• In late June 2026, Kimberly-Clark and Suzano completed the formation of Arbex, a US$3.40 billion joint venture that now operates as an independent global tissue and hygiene business managing brands such as Kleenex, Scott, Cottonelle, Andrex, and Viva across more than 70 markets.
• Arbex’s launch, staffed with senior leaders drawn from both Kimberly-Clark and Suzano, underscores how deeply this transaction reshapes Kimberly-Clark’s portfolio, operations, and long-term business focus.
• Next, we’ll examine how Kimberly-Clark’s creation of Arbex as a focused joint venture could reshape its investment narrative and future business mix.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 31 companies in the world exploring or producing it. Find the list for free.

Kimberly-Clark Investment Narrative Recap

To own Kimberly-Clark today, you need to believe in a simpler, higher-margin personal care company after carving out much of its international tissue and professional operations into Arbex. The key near-term catalyst is how effectively Kimberly-Clark can refocus on core North American and personal care categories, while the biggest risk is that this increased concentration amplifies any weakness in diapers and related segments. The latest Arbex leadership appointments do not materially change that risk-reward balance in the short term.

What does matter near term is Kimberly-Clark’s June 2026 shift within the Russell indices, moving out of the Russell Top 200 benchmarks and into the Russell Midcap, Midcap Growth, and Midcap Value indices. This change could alter who holds the stock, how it trades around index rebalancings, and how investors frame Kimberly-Clark’s size and profile, all of which intersect with the new, more focused business mix after Arbex.

Yet beneath Kimberly-Clark’s streamlined story, the heightened reliance on North America and personal care leaves investors exposed to...

Kimberly-Clark's narrative projects $18.4 billion revenue and $2.7 billion earnings by 2029. This requires 3.5% yearly revenue growth and about a $1.0 billion earnings increase from $1.7 billion today.

Uncover how Kimberly-Clark's forecasts yield a $114.67 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Some of the most pessimistic analysts were assuming revenue would shrink about 2.9 percent a year and earnings reach only about US$2.8 billion by 2028, which is a very different story from investors who see Arbex and margin efforts as potential supports for faster improvement.

Explore 6 other fair value estimates on Kimberly-Clark - why the stock might be worth 10% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Kimberly-Clark research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Kimberly-Clark research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Kimberly-Clark's overall financial health at a glance.

Searching For A Fresh Perspective?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Find 41 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.